A Phase 4 interventional study of Enstilar and Vehicle in Plaque Psoriasis, sponsored by L.H. Kircik, M.D.. Completed at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by L.H. Kircik, M.D. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 499th largest by enrollment of the 673 interventional ones that give a count, is one of 50 that started in 2017, is one of 117 in phase 4, and was the 480th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 50 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with L.H. Kircik, M.D. as lead sponsor.
L.H. Kircik, M.D. has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam.
Approximately 50 subjects from 4 sites will be enrolled in this investigator-blind study. Subjects will be randomized 1:1 to Otezla plus Enstilar foam or Otezla plus vehicle foam and all adverse events and concomitant medications will be recorded.
Subjects will attend a screening visit/baseline visit and those with plaque-type psoriasis who have been started on commercial Otezla in the last 7 days will be randomized to study treatment as outlined above.
Enstilar or the vehicle will be initiated for the first 4 weeks and then Otezla will be continued as monotherapy for the next 8 weeks. Enstilar or the vehicle will be reinitiated for the last 4 weeks of the study. Total study period is 16 weeks and study visits will occur as follows: screening/baseline, week 1, 2, 3, 4, week 12, and week 16. Study assessments at each visit will be PASI, BSA, PGA, Itch VAS, DLQI, and standard medical assessments. There will be standard medication/treatment and washout periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
I. Outpatient, male or female subjects of any race, 18 years of age or higher. Female subjects of must have a (-)UPT (urine pregnancy test) result at within 7 days of the first dose of study drug and practice a reliable method of throughout the study;
A female is considered of childbearing potential unless she is:
Reliable methods of contraception are:
[Exception: Female subjects of CBP (child bearing potential) who are not sexually active are not required to practice a reliable method of contraception and may be enrolled at the Investigator's discretion provided they are counseled to remain sexually inactive for the duration of the study and understand the risks involved in getting pregnant during the study.] ii. Subjects with moderate plaque type psoriasis who have been started on commercial Otezla within the last 10 days.
iii. Physician Global Assessment (PGA) score of 3. iv. Able to understand study requirements and sign /HIPAA forms.
Exclusion Criteria:
I. Female subjects who are pregnant, breast-feeding, or who are of and not practicing a reliable method of , or male subjects planning a pregnancy with their spouse or partner while in the study.
ii. History of hypercalcemia or vitamin D toxicity or history of significant renal or hepatic disease iii. Patients with guttate, erythrodermic, or pustular psoriasis iv. Serious skin condition (other than psoriasis) or uncontrolled medical condition (in the opinion of the investigator).
v. Skin conditions (e.g.eczema) other than psoriasis that may interfere with evaluations of psoriasis.
vi. Known to Enstilar Foam or any of its components. vii. Current drug or alcohol abuse (Investigator opinion). viii. Subject unable to commit to all the assessments required by the protocol. ix. Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to the Screening Visit.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
Drug: Enstilar · Drug: Otezla
Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
Drug: Vehicle · Drug: Otezla
Enstilar foam applied to affected areas daily
Also known as: calcipotriene and betamethasone dipropionate
vehicle foam applied to affected areas once daily
Otezla 30mg
Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16
PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.) The body is divided into 4 sections: head (10% of total body surface area,) arms (20%,) trunk(30%,) and legs (40%.) Each of these is scored by itself and the 4 scores then combined to obtain thePASI. For each body area, the percent of skin area involved is estimated and graded based on this value (0=0% of area involved, 1=\<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%.) Within each area, the severity of disease is based on 3 clinical signs: erythema or redness, induration or thickness, and desquamation or scaliness. Each is graded on a scale from 0(none) to 4(maximum.) The sum of all 3 parameters is calculated for each body section, multiplied by the area score for that section and then multiplied by the weight of that section (.1for head, .2 arms, .3 trunk and .4 legs)
Time frame: 16 weeks
Percent of Subjects With PASI 75 at Week 4 and Week 12
Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)
Time frame: 4 weeks, 12 weeks
Percent of Subjects With PASI 90 and 100 at Week 16
Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)
Time frame: 16 weeks
Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16
The Investigator will rate the severity of of disease based on the assessment of 3 clinical signs (erythema, induration, desquamation) wherein 0=no signs of psoriasis, 1=almost clear, 2=mild, 3=moderate, 4=severe
Time frame: 4 weeks, 12 weeks, 16 weeks
Global Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16
The Itch VAS (Visual Analog Scale) is completed by subjects wherein they are asked to rate the severity of their itching over the last 48 hours on a scale from 0 (no itching) to 10 (unbearable itching); low scores indicate a better outcome.
Time frame: 4 weeks, 12 weeks, 16 weeks
Global Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16
The DLQI is a 10-question tool completed by subjects to ascertain the severity of disease based on the extent to which disease interferes with daily life. Each question is scored according to the response wherein Very Much =3, A lot=2, A little=1 and Not at all=0. The sum of all responses is then recorded on a scale from 0 to 30, lower scores indicating better quality of life.
Time frame: 4 weeks, 12, weeks, 16 weeks
| Milestone | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| Started | 14 | 14 |
| Completed | 13 | 10 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.) The body is divided into 4 sections: head (10% of total body surface area,) arms (20%,) trunk(30%,) and legs (40%.) Each of these is scored by itself and the 4 scores then combined to obtain thePASI. For each body area, the percent of skin area involved is estimated and graded based on this value (0=0% of area involved, 1=\<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%.) Within each area, the severity of disease is based on 3 clinical signs: erythema or redness, induration or thickness, and desquamation or scaliness. Each is graded on a scale from 0(none) to 4(maximum.) The sum of all 3 parameters is calculated for each body section, multiplied by the area score for that section and then multiplied by the weight of that section (.1for head, .2 arms, .3 trunk and .4 legs)
| Participants | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16 | 7 | 2 |
Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)
| Participants | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| week 4 | 7 | 1 |
| week 12 | 4 | 2 |
Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)
| Participants | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| PASI 90 | 4 | 2 |
| PASI 100 | 1 | 0 |
The Investigator will rate the severity of of disease based on the assessment of 3 clinical signs (erythema, induration, desquamation) wherein 0=no signs of psoriasis, 1=almost clear, 2=mild, 3=moderate, 4=severe
| Participants | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| week 4 — clear | 1 | 0 |
| week 4 — almost clear | 5 | 1 |
| week 4 — mild | 7 | 4 |
| week 4 — moderate | 1 | 9 |
| week 4 — severe | 0 | 0 |
| week 12 — clear | 1 | 0 |
| week 12 — almost clear | 1 | 3 |
| week 12 — mild | 5 | 4 |
| week 12 — moderate | 6 | 7 |
| week 12 — severe | 1 | 0 |
| week 16 — clear | 1 | 1 |
| week 16 — almost clear | 8 | 1 |
| week 16 — mild | 4 | 3 |
| week 16 — moderate | 0 | 9 |
| week 16 — severe | 1 | 0 |
The Itch VAS (Visual Analog Scale) is completed by subjects wherein they are asked to rate the severity of their itching over the last 48 hours on a scale from 0 (no itching) to 10 (unbearable itching); low scores indicate a better outcome.
| scale unit | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| week 4 | 2 ± 2 | 5 ± 3 |
| week 12 | 4 ± 3 | 4 ± 3 |
| week 16 | 3 ± 3 | 4 ± 3 |
The DLQI is a 10-question tool completed by subjects to ascertain the severity of disease based on the extent to which disease interferes with daily life. Each question is scored according to the response wherein Very Much =3, A lot=2, A little=1 and Not at all=0. The sum of all responses is then recorded on a scale from 0 to 30, lower scores indicating better quality of life.
| score on a scale | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| week 4 | 2 ± 2 | 5 ± 4 |
| week 12 | 5 ± 5 | 5 ± 4 |
| week 16 | 3 ± 4 | 6 ± 6 |
Collected over screening to week 16. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Otezla Plus Enstilar Foam | 0/14 (0%) | 1/14 (7.1%) | 5/14 (35.7%) |
| Otezla Plus Vehicle Foam | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Event | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| sinus tachycardiaCardiac disorders | 1/14 | 0/14 |
| upper respiratory infectionInfections and infestations | 1/14 | 0/14 |
| chronic obstructive pulmonary disease exacerbationRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 |
| thrombocytopeniaBlood and lymphatic system disorders | 1/14 | 0/14 |
| shortness of airRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 |
| Event | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam |
|---|---|---|
| rhinorrheaRespiratory, thoracic and mediastinal disorders | 2/14 | 0/14 |
| upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 1/14 | 2/14 |
| increased joint pain generalizedMusculoskeletal and connective tissue disorders | 1/14 | 1/14 |
| chest congestionRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 |
| squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/14 | 0/14 |
| overactive bladderRenal and urinary disorders | 1/14 | 0/14 |
| dyspnea at restRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 |
| fall at homeGeneral disorders | 1/14 | 0/14 |
| hypertensionCardiac disorders | 0/14 | 1/14 |
| compressed lumbar discMusculoskeletal and connective tissue disorders | 0/14 | 1/14 |
| Age, Continuous(years) | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam | Total |
|---|---|---|---|
| Mean | 55 ± 17 | 52 ± 12 | 53 ± 14 |
| Sex: Female, Male(Participants) | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam | Total |
|---|---|---|---|
| Female | 4 | 5 | 9 |
| Male | 10 | 9 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 14 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Otezla Plus Enstilar Foam | Otezla Plus Vehicle Foam | Total |
|---|---|---|---|
| United States | 14 | 14 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Oct 2018, 12 months.
Results were first posted in Mar 2019, 5 months after primary completion.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 12 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.